AVIR
HealthcareAtea Pharmaceuticals, Inc.
$3.41
$-0.07 (-2.01%)
Jan 5, 2026
Price History (1Y)
Analysis
Atea Pharmaceuticals, Inc. (AVIR) operates within the healthcare sector and biotechnology industry, employing 56 individuals. The company's market capitalization stands at $266.41 million. Financially, Atea Pharmaceuticals has reported a net income of -$147,024,992 over the trailing twelve months, with an EBITDA of -$158,774,000 and free cash flow of -$76,438,752. Additionally, the company boasts a substantial amount of cash on hand at $329.31 million, accompanied by a minimal debt of $1.04 million. Marginally, Atea Pharmaceuticals has exhibited 0.0% gross margin, operating margin, and profit margin. Valuation metrics reveal an unfavorable forward P/E ratio of -1.95, alongside a price to book ratio of 0.84. The company's cash-to-debt ratio stands at approximately 319,000.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $266.41M
- P/E Ratio
- N/A
- 52-Week High
- $4.02
- 52-Week Low
- $2.46
- Avg Volume
- 417.44K
- Beta
- 0.08
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 56